Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment

CRISTINA OLIVERAS-FERRAROS1,2, ANNA MASSAGUER VALL-LLORENA3, ALEJANDRO VAZQUEZ-MARTIN1,2, DOLORES CARRION SALIP3, BERNARDO QUERALT2,4, SILVIA CUFÍ1,2, BEGOÑA MARTIN-CASTILLO2,5, JOAQUIM BOSCH-BARRERA2,4, JOAN BRUNET2,4, RAFAEL DE LLORENS3 and JAVIER A. MENENDEZ1,2

1Translational Research Laboratory, Catalan Institute of Oncology (ICO); 2Girona Biomedical Research Institute (IdIBGi); 3Biochemistry and Molecular Biology Unit, Department of Biology, University of Girona; 4Medical Oncology, Catalan Institute of Oncology (ICO); 5Unit of Clinical Research, Catalan Institute of Oncology (ICO), Girona, Catalonia, Spain

Received January 24, 2012; Accepted February 28, 2012

DOI: 10.3892/or.2012.1732

Abstract. The recent identification of HER2 gene amplification as a novel predictor of resistance to the EGFR (HER2)-targeted antibody cetuximab and of response to combination therapies against EGFR and HER2 in wild-type KRAS tumor settings may represent a further step toward personalized medicine for patients with colorectal cancer. Herein, we show that transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification is a molecular phenomenon that takes place in EGFR-dependent, wild-type KRAS squamous cell carcinoma (SCC) cells that acquire resistance to cetuximab. Since cetuximab activity against cetuximab-refractory SCC cells can be fully restored in the presence of the anti-HER2 monoclonal antibody trastuzumab, our findings suggest that, beyond HER2 gene amplification, we might need to redefine the threshold values for HER2 positivity to improve the accuracy of the selection of cetuximab-refractory patients with wild-type KRAS that may benefit from receiving a cetuximab/trastuzumab combination.

Introduction

Three recent studies aimed at delineating new mechanisms of therapeutic resistance to the anti-HER1 (EGFR) antibody cetuximab (Ctx; Erbitux®) have concurrently identified aberrant HER2 (ERBB2) signaling as a novel mechanism for mediating Ctx resistance in carcinomas with wild-type KRAS. Yonesaka et al (1) showed that activation of HER2 signaling in cultured cancer cells, through either HER2 gene amplification or upregulation of the HER2/HER3 ligand heregulin, is sufficient to cause Ctx resistance. Accordingly, colorectal cancer patients exhibiting either de novo or acquired resistance to Ctx-based therapeutic regimens were found to have HER2 gene amplification or high levels of circulating heregulin. In their hands, HER2 inhibition or disruption of HER2/HER3 heterodimerization restored the antitumor activity of Ctx in vitro and in vivo. The suggestion of Yonesaka that a combination of HER2 inhibitor and Ctx treatment may represent a rational therapeutic strategy that should be assessed in colon cancer patients with Ctx-resistant carcinomas was also confirmed in a novel in vivo model of bladder carcinoma with acquired resistance to Ctx.

Quesnelle and Grandis (2) showed that increased phosphorylation of a C-terminal fragment of HER2 mediates Ctx resistance both in vitro and in vivo because afatinib (BIBW-2992), an irreversible dual HER1/HER2 tyrosine kinase inhibitor (TKI), successfully inhibits the growth of Ctx-resistant carcinoma cells. Upon production of large xenograft cohorts from 85 patient-derived, genetically characterized metastatic colorectal cancer samples (‘xenopatients’), Bertotti et al (3) generated genotype-Ctx response correlations indicating that HER2 gene amplification specifically occurs in a subset of Ctx-resistant, wild-type KRAS/NRAS/BRAF/PIK3CA cases. In agreement with Yonesaka et al (1), Bertotti et al (3) found a significant enrichment of HER2 gene amplification in clinically Ctx-unresponsive wild-type KRAS patients. Importantly, combined inhibition of EGFR and HER2 induced overt, long-lasting tumor regression in HER2 gene-amplified xenopatients. As discussed by Ciardiello and Normanno (4), the identification of HER2 as a predictor of resistance to the EGFR-targeted antibody Ctx and of response to combination therapies against EGFR and HER2 in wild-type KRAS tumor settings may represent a further step toward personalized medicine for patients with colorectal cancer.

Correspondence to: Dr Javier A. Menendez, Catalan Institute of Oncology, Girona (ICO-Girona), Dr. Josep Trueta University Hospital, Avenida de França s/n, E-17007 Girona, Catalonia, Spain E-mail: jmenendez@iconcologia.net; jmenendez@idibgi.org

Key words: cetuximab, KRAS, EGFR, HER2, trastuzumab, lapatinib
We now reveal that the acquisition of secondary resistance to Ctx in squamous cell carcinoma (SCC) cells is accompanied also by transcriptional upregulation of HER2 expression in absence of HER2 gene amplification, which is amenable to inhibition by HER2-targeted drugs. As the Ctx anti-tumoral activity was fully restored in the presence of the anti-HER2 monoclonal antibody trastuzumab, our current findings suggest that we need to redefine the threshold values for HER2 positivity beyond the sole presence of HER2 gene amplification to improving the accuracy of the selection of Ctx-refractory patients with wild-type KRAS that might benefit from receiving a Ctx/trastuzumab combination.

Materials and methods

Drugs. Dual HER1/HER2-TKI1 lapatinib (GW572016; Tykerb®) was kindly provided by GlaxoSmithKline (GSK), Corporate Environment, Health & Safety (Brentford, Middlesex, UK). Stock solution of lapatinib (10 mmol/l) were prepared in DMSO and stored in aliquots in the dark at -20°C until utilization. Cetuximab (Erbitux®) and trastuzumab (Herceptin®) were kindly provided by Hospital Universitari de Girona Dr Josep Trueta Pharmacy (Girona, Spain). Cetuximab was solubilized with 10 mmol/l NaCl of potassium phosphate buffer (PBS) pH 7.2 in bacteriostatic water for injection purposes (stock solution at 2 mg/ml), stored at 4°C and used within 1 month. Trastuzumab was solubilized in bacteriostatic water for injection containing 1.1% benzyl alcohol (stock solution at 21 mg/ml), stored at 4°C and used within 1 month. For experimental use, experimental agents were prepared fresh from stock solutions and were diluted with cell growth media immediately before use.

Cell viability. Concentration-effect curves were generated as a plot of the fraction of surviving cells versus drug concentration using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reduction assay as previously described (11).

Real-time quantitative PCR (Taqman) analysis. RNA was isolated using the Qiagen RNeasy Mini kit and the expression of HER1 (EGFR), HER2 and HER3 genes was quantified by real-time quantitative PCR or Taqman using 100 ng of total RNA per reaction, as described previously (10,20,21). The sequences of the primer/probe sets used for this analysis are: EGFR (HER1) 5'GCTCTGAGTGTCATCTATTCAAGCAC-3' (F), 5'TGCTACTGTCATTGCACCTTG-3' (R), and 5'-FAM-AGCTCTGACCAGGCGTATT-3' (P); HER2 5'TCTGGACGTGCCAGTGTGAA-3' (F), 5'TGCTCCCTGCCACAACAGGGCATTTT-TAMRA-p-3' (P); HER3 5'TGCTCCCTGCCACAACAGGGCATTTT-TAMRA-p-3' (F), where F and R are the forward and reverse primers, respectively, and P is the Taqman probe (FAM as reporter and TAMRA as quencher). Taqman reaction was done in a standard 96-well plate format with ABI 7500 real-time quantitative PCR system. For data analysis, raw ΔCt was first normalized to a housekeeping gene (i.e., TBT: TATA-Box Binding Protein) for each sample to get ΔCt. The normalized ΔCt was then calibrated to control (untreated) samples to get ΔΔCt. In the final step of data analysis, the ΔΔCt, were converted to fold-changes (2-ΔΔCt) relative to untreated controls.

HER2-specific enzyme-linked immunosorbent assay (ELISA). Determination of HER2 protein content was performed with a commercially available quantitative ELISA (Oncogene Science, Bayer Diagnostics) according to the manufacturer's protocol. The concentrations of HER2 in test samples (in nanograms of HER2 per milligram of total protein) were determined by interpolation of the sample absorbances from the standard curve. Each experiment was performed in duplicate wells.

Establishment of long-term accommodation to Ctx in EGFR gene-amplified, wild-type KRAS A431 SCC cells. Over a minimum period of 6 months, cultures of A431 vulvar squamous carcinoma cells (originally obtained from the American Type Culture Collection, Manassas, VA, USA) were continuously exposed to increasing concentrations of Ctx. A431 epidermoid carcinoma cells were chosen based on two primary criteria: (1) these EGFR-overexpressing cells are exquisitely sensitive to Ctx; and (2) A431 cells have neither EGFR Tyrosine Kinase Domain or KRAS mutations. Commencing with the Inhibitory Concentration 50 (IC50) of Ctx (~25 µg/ml), the exposure dose was progressively increased 2-3 weeks until four dose doubling had been successfully achieved. Controlled parental cells were cultured in parallel and exposed to the PBS vehicle. We established two Long Term (LT)-Ctx adapted A431 pooled populations that were then maintained in continuous culture with the maximal achieved dose of Ctx. When challenged to Ctx doses as high as 200 µg/ml, they retained a >90% active metabolic status (as assessed by MTT-based cell viability assays) compared to Ctx-naïve A431 parental cells (which decreased their ability to metabolize MTT by ~70-80% following treatment with an equivalent dose of Ctx).

Parental A431 cells and LT-Ctx adapted pools were routinely grown in Dulbecco's modified Eagle's medium (DMEM, Gibco® Cell Culture Systems, Invitrogen S.A., Barcelona, Spain) containing 10% heat-inactivated fetal bovine serum (FBS, Bio-Whittaker, Inc., Walkersville, MD, USA), 1% L-glutamine, 1% sodium pyruvate, 50 U/ml penicillin, and 50 µg/ml streptomycin (culture media for LT-Ctx adapted pools included 100 µg/ml Ctx, which was freshly added during culture splitting). Cells were maintained at 37°C in a humidified atmosphere of 95% air/5% CO2. Cells were screened periodically for Mycoplasma contamination.

Statistics. Two-group comparisons were performed by the Student t test for paired and unpaired values. Comparisons of means of ≥3 groups were performed by ANOVA, and the existence of individual differences, in case of significant F values at ANOVA, tested by Scheffé's multiple comparisons. In all the cases statistical analyses were carried out with XLSTAT (Addinsoft™) and P<0.01 was considered to be significant.

Results

HER2 overexpression is sufficient to impede cetuximab functioning in EGFR-overexpressing cancer cells. To definitively test the hypothesis that HER2 upregulation is sufficient to cause Ctx resistance, we used MCF10A cells, a useful in vitro
system for analyzing the effects of the expression of specific cancer- and chemoresistance-related genes (e.g., HER2) in a non-transformed, near diploid, spontaneously immortalized genetic background (5-7). In addition to naturally expressing very low levels of HER2, MCF10A cells constitutively express high levels of EGFR and are dependent on EGF for optimal growth. Hence, overexpression of HER2 in these cells recapitulates the common clinical situation of HER1 and HER2 co-overexpression, and with the addition of EGF, the paracrine/autocrine stimulation of HER receptors-driven oncogenic signaling is also recapitulated. MCF10A cells acquire both an \textit{in vitro} transformed and an \textit{in vivo} tumorigenic phenotype following transfection with appropriate vectors containing the HER2 gene (5-8).

We employed MCF10A cells that were engineered to overexpress the wild-type form of human HER2 by retroviral infection, thus avoiding undesirable clone-related effects (Fig. 1, left). When HER2-specific ELISA assays were used to quantitatively measure the change in the concentration of the HER2 protein following retroviral infection and stable selection, empty vector-transduced MCF10A/pBABE cells and MCF10A/HER2 cells were found to express 60 ng of HER2 mg protein\(^{-1}\) and 2,200 ng of HER2 mg\(^{-1}\) protein, respectively (8). Of note, the retrovirally driven upregulation of HER2 in MCF10A/HER2 cells can be considered to constitute \textit{bona fide} HER2 overexpression because the HER2 protein levels are comparable to or greater than those found in cancer cell lines that naturally exhibit \textit{HER2} gene amplification and HER2 protein overexpression [e.g., \(>900\) HER2 ng/mg protein in SKBR3 and BT-474 breast carcinoma cell lines (9)]. More importantly for this study, the half-maximal inhibitory concentration (IC\(_{50}\)) of Ctx was as low as 25 µg/ml in the parental MCF10A cells (Fig. 1C, right). However, in equivalent dose-response, MTT-based cell viability analyses of Ctx-treated MCF10A/HER2 cells, the IC\(_{50}\) value for viability was not reached, even at doses as high as 200 µg/ml (Fig. 1, right).

Acquired (secondary) resistance to Ctx is accompanied by transcriptional upregulation of HER2 overexpression in squamous cell carcinoma cells. Since predictors of efficacy in non-small cell lung carcinomas, in which \textit{KRAS} mutations do not predict Ctx efficacy, and in head and neck squamous cell carcinomas with intact \textit{KRAS} signaling are also lacking, we propose that our recently established pre-clinical models of EGFR gene-amplified wild-type \textit{KRAS} A431 squamous cell carcinoma, in which cells are chronically adapted to grow in the presence of Ctx (10-12), could be used to determine if the HER2 expression status is significantly altered during and/or after treatment with Ctx. We first performed real-time (kinetic) RT-PCR analyses to quantitatively track the transcriptional evolution of the entire family of HER receptors [i.e., EGFR (HER1), HER2, HER3, and HER4] during Ctx-induced deactivation of the EGFR/RAS/MAPK pathway. Analyzing the changes in the gene expression profiles of the HER1/-2/-3/-4 receptors during acute (i.e., 6 h) treatment with Ctx revealed that Ctx treatment significantly increased HER2 mRNA expression by \~3-fold (Fig. 2A, left). An equivalent upregulation of HER3 mRNA (3-fold) was observed in response to acutely added Ctx. The expression status of EGFR (HER1) at the mRNA level remained unaltered following Ctx exposure. HER4 expression was not detectable.
by RT-PCR in A431 cells (data not shown). Using pre-clinical models of acquired Ctx resistance, which were developed in our laboratory by chronically adapting A431 cells to grow in the continuous presence of Ctx for a minimum of 6 months (10-12), we observed that mRNA levels of HER2 and HER3 were drastically upregulated by ~7- and 8-fold, respectively, in one of the Ctx-unresponsive pooled A431 cell populations (Fig. 2A, left). Upregulations in the HER2 and HER3 mRNA levels of >4-fold were detected in a second pooled population of Ctx-resistant A431 cells (data not shown). Notably, this upregulation in the HER2 and HER3 mRNA levels remained unaltered in response to Ctx challenge (Fig. 2A, left).

**Co-exposure to the anti-HER2 monoclonal antibody trastuzumab reverses acquired resistance to Ctx in squamous cell carcinoma cells.** ELISA-based determination of HER2 expression confirmed that the HER2 protein is significantly upregulated in A431 cells once resistance to Ctx is acquired (Fig. 2A, right). However, ELISA experiments showed that the changes in expression of the HER2 protein do not match the more prominent upregulation of HER2 at the mRNA level. Although the ultimate molecular mechanism underlying this lack of correlation between the increase in HER2 mRNA levels (up to 7-fold) and the smaller increase in HER2 protein expression (~2-fold) is unclear, we evaluated the functional activity of the transcriptionally upregulated HER2 protein and its causal relationship with the acquisition of resistance to Ctx (Fig. 2B, left). When we added the dual HER1/HER2 TKI lapatinib (Tykerb) to the culture medium of Ctx-resistant A431 cells already containing cetuximab (to simulate the treatment progression used in the clinic), we observed that Ctx-resistant A431 squamous cancer cells not only retained...
lapatinib sensitivity but were slightly more sensitive than Ctx-naive A431 parental cells to the growth-inhibitory effects of lapatinib (Fig. 2B, right). This suggests an increase in HER2 signaling in Ctx-resistant cells, which was confirmed using the mono-HER2 inhibitor trastuzumab (Herceptin). While HER1 (EGFR)-dependent A431 parental cells were also refractory to trastuzumab-induced blockade of HER2, a reduction of ~50% in MTT dye uptake, which correlates with cell viability, was observed in trastuzumab-treated Ctx-resistant A431 cells (Fig. 2B, right). We believe that these qualitative and quantitative differences in the antitumor efficacy of trastuzumab are a direct consequence of the pro-survival function driven by the transcriptional upregulation of HER2 in EGFR-positive A431 cells that have acquired resistance to Ctx.

Discussion

Our current findings reveal that EGFR-positive, KRAS wild-type cancer cells with acquired resistance to Ctx can become addicted to HER2-driven signaling and can therefore benefit from subsequent treatment with the anti-HER2 monoclonal antibody trastuzumab, providing a rationale for the use of HER2-targeted therapies in the presence of Ctx resistance. This phenomenon should be taken into account during the design of studies addressing the role of HER2 in inherent (primary) and acquired (secondary) Ctx resistance and for developing strategies for testing Ctx in combination with HER2 inhibitors such as trastuzumab in the absence of HER2 amplification. The benefits of adjuvant trastuzumab may not be limited to patients with HER2 gene amplification (13,14), and trastuzumab efficiently triggers receptor-enhanced chemosensitivity (REC) when combined with chemotherapy in cell lines with low-to-intermediate HER2 expression, i.e., without HER2 overexpression (15,16). Moreover, trastuzumab may work by targeting cells with tumor-propagating properties; such cells, notably, are enriched in Ctx-resistant pooled populations of A431 cells (11), which have increased levels of HER2 protein compared with the bulk cell population, in which HER2 gene amplification is unmodified (17-19). Although this is an in vitro study, if our current data were to be validated with clinical samples, the threshold values for HER2 positivity may need to be redefined for Ctx-refractory patients with wild-type KRAS that might benefit from receiving a Ctx/trastuzumab combination. Theoretically, the guidelines regarding trastuzumab administration would then need to include more Ctx-refractory cases than those selected based solely on the presence of HER2 gene amplification.

Acknowledgements

The work in the laboratory of Javier A. Menendez was supported by the Instituto de Salud Carlos III (Ministerio de Sanidad y Consumo, Fondo de Investigación Sanitaria (FIS), Spain, Grants CP05-00090 and PI06-0778 and RD06-0020-0028), the Fundación Científica de la Asociación Española Contra el Cáncer (AECC, Spain), and by the Ministerio de Ciencia e Innovación (SAF2009-11579, Plan Nacional de I+D+I, MICINN, Spain). Alejandro Vazquez-Martin is the recipient of a Sara Borrell post-doctoral contract (CD08/00283, Ministerio de Sanidad y Consumo, Fondo de Investigación Sanitaria -FIS-, Spain). Silvia Cufí is the recipient of a Research Fellowship (Formación de Personal Investigador, FPI) from the Ministerio de Ciencia e Innovación (MICINN, Spain). Cristina Oliveras-Ferrarros received a research salary from a Grant Award by the ‘Fundacion Salud 2000’, which is promoted by Merck Serono (Madrid, Spain).

References


